CTMX: CytomX Therapeutics, Inc.
About
CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company, which engages in the development of conditionally activated, biologics localized to the tumor microenvironment. The company was founded by Frederick W. Gluck and Nancy E. Stagliano in September 2010 and is headquartered in South San Francisco, CA.
Current Value
$0.901 Year Return
Current Value
$0.901 Year Return
Key Details
Market Cap
$69.86M
P/E Ratio
5.26
1Y Stock Return
-31.59%
1Y Revenue Growth
33.66%
Dividend Yield
0.00%
Price to Book
-3.0
Strategies that include CTMX
Stock's related to CTMX
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| SRDX | 62.78% | $559.12M | +15.64% | 0.00% |
| ATEN | 53.86% | $1.21B | +34.32% | 1.46% |
| PINS | 46.84% | $20.07B | -5.95% | 0.00% |
| TECH | 45.87% | $10.55B | +4.49% | 0.48% |
| RCKY | 45.41% | $155.86M | -17.74% | 2.95% |
| OSW | 40.82% | $1.95B | +65.90% | 0.21% |
| TMDX | 40.05% | $2.78B | +22.14% | 0.00% |
| AMCR | 38.74% | $14.29B | +7.03% | 4.94% |
| GRMN | 38.42% | $39.82B | +73.79% | 1.43% |
| TRTX | 34.96% | $716.21M | +56.64% | 10.91% |
| VRSK | 31.70% | $39.77B | +17.45% | 0.53% |
| UTHR | 30.80% | $16.10B | +56.54% | 0.00% |
| PFE | 26.35% | $142.24B | -17.16% | 6.73% |
| PRCT | 25.84% | $5.09B | +177.49% | 0.00% |
| SUNS | 25.58% | $105.89M | +35.31% | 1.37% |
| AX | 24.82% | $4.55B | +107.29% | 0.00% |
| LXFR | 24.60% | $387.04M | +72.02% | 3.60% |
| NARI | 24.59% | $2.98B | -11.66% | 0.00% |
| VTYX | 24.40% | $125.87M | -23.61% | 0.00% |
| PSTX | 23.94% | $269.98M | +6.13% | 0.00% |
Uncorrelated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| WTI | 0.01% | $291.77M | -42.77% | 2.01% |
| DNOW | -0.01% | $1.52B | +40.10% | 0.00% |
| EPAC | -0.02% | $2.55B | +69.58% | 0.09% |
| RILY | 0.02% | $145.72M | -79.86% | 20.75% |
| CNH | 0.02% | $13.83B | +9.71% | 4.23% |
| ECL | -0.03% | $69.18B | +30.92% | 0.93% |
| PJT | -0.03% | $3.69B | +85.94% | 0.65% |
| RELX | 0.04% | $84.12B | +19.85% | 1.71% |
| ANET | -0.04% | $118.95B | +75.41% | 0.00% |
| CNSL | 0.05% | $548.51M | +9.98% | 0.00% |
| ULH | -0.06% | $1.25B | +97.14% | 0.88% |
| AFRM | -0.06% | $20.09B | +155.53% | 0.00% |
| ALGM | 0.07% | $3.59B | -31.01% | 0.00% |
| PDCO | -0.07% | $1.80B | -36.77% | 5.12% |
| ON | -0.07% | $28.38B | -2.54% | 0.00% |
| MRK | 0.07% | $244.21B | -5.55% | 3.18% |
| ANSS | 0.07% | $29.69B | +13.34% | 0.00% |
| LOVE | 0.08% | $513.90M | +78.25% | 0.00% |
| ZIMV | 0.08% | $363.48M | +47.32% | 0.00% |
| FET | 0.08% | $182.04M | -34.05% | 0.00% |
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| LEG | -46.19% | $1.54B | -50.75% | 9.00% |
| CVS | -44.76% | $70.18B | -18.08% | 4.72% |
| SBUX | -41.72% | $111.45B | -5.15% | 2.37% |
| ASTE | -39.76% | $820.86M | +13.24% | 1.45% |
| CDW | -38.01% | $23.19B | -19.73% | 1.42% |
| SWKS | -35.16% | $13.35B | -10.80% | 3.29% |
| GPN | -34.67% | $29.20B | +2.38% | 0.87% |
| DBRG | -28.33% | $2.15B | -23.92% | 0.32% |
| KHC | -27.91% | $36.98B | -10.45% | 5.23% |
| CLBK | -27.82% | $1.89B | +4.93% | 0.00% |
| OI | -27.81% | $1.88B | -17.67% | 0.00% |
| HI | -26.15% | $2.21B | -18.30% | 2.85% |
| EL | -25.70% | $23.26B | -46.08% | 4.10% |
| CLX | -25.17% | $20.81B | +20.66% | 2.88% |
| GIC | -24.20% | $1.04B | -25.63% | 3.67% |
| ENLC | -23.70% | $7.13B | +20.56% | 3.39% |
| YUM | -22.26% | $36.88B | +3.04% | 1.98% |
| CCCS | -21.91% | $7.37B | +2.97% | 0.00% |
| COR | -21.04% | $47.48B | +21.20% | 0.86% |
| RYI | -20.75% | $751.91M | -19.47% | 3.18% |
ETF's related to CTMX
News
Yahoo
Per GRFS, Brookfield's offer to buy its entire outstanding share capital for 6.45 billion euros significantly undervalues GRFS' prospects and long-term potential.
Yahoo
CytomX Therapeutics (CTMX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Yahoo
The CHMP's opinion is based on late-stage data, which show that treatment with AZN's Tagrisso extends progression-free survival by more than three years in certain NSCLC patients.
Yahoo
CytomX Therapeutics ( NASDAQ:CTMX ) Third Quarter 2024 Results Key Financial Results Revenue: US$33.4m (up 27% from 3Q...
Yahoo
Q3 2024 CytomX Therapeutics Inc Earnings Call
SeekingAlpha
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Q3 2024 Earnings Conference Call November 7, 2024 5:00 PM ETCompany ParticipantsChris Ogden - CFOSean A.
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.